The Financial Times and Julphar would like to thank all of the speakers and delegates that participated in the FT Julphar MENA Biotechnology and Biosimilars Forum for making this innaugural gathering of industry experts, investors, policy makers and regulators from across the region and internationally such a success.

With the growing affluence of their citizens, the increasing relevance of lifestyle diseases and the expansion of the healthcare infrastructure, the countries of the MENA region represent a significant opportunity for life science companies.  This one day conference discussed the emerging opportunities and challenges facing the biotechnology sector in the MENA.

Speakers Included: Christopher Hansung Ko Chief Executive Officer Samsung Bioepis Amin Hussain Al Amiri Undersecretary for Medical Practice and License UAE Ministry of Health Marie-Christine Bielsky Senior Medical Assessor, Biologicals and Biotechnology Unit, Licensing Division Medicines and Healthcare Products Regulatory Agency, UK (MHRA) Tawfik Khoja Director General Health Ministers Council for Cooperation, SGH Ayman Sahli Chief Executive Officer Julphar-Gulf Pharmaceutical Industries Thomas Lönngren Strategic Adviser NDA Regulatory Science; Former Executive Director European Medicines Agency (EMA)

Chaired By: Andrew Jack Pharmaceuticals Correspondent Financial Times  Forum Preview Video:

Post Event Media: Attendees of the event can access the presentations here by entering the password provided to them by email. Photos from the event can be found on Flickr.